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T follicular cells help B cells to drive germinal center formation. In this issue of Immunity, Ballesteros-Tato
et al. (2012) demonstrate that high amounts of interleukin-2 inhibit production of this critical T effector subset.Antigen-specific long-lived plasma and
memory B cells originate in germinal
centers (GCs) and provide effective and
lasting protection against infection. The
GC reaction is controlled by antigen-
specific cognate interactions between T
follicular (Tfh) and B cells bordering the
T cell zone and the follicle (Vinuesa and
Cyster, 2011). The migration of T and B
cells to these locations and subsequent
intercellular interactions is facilitated by
upregulation of the chemokine receptor
CXCR5. Importantly, antigen-priming
and costimulation of CD4+ T cells, the
latter through engagement of CD28,
ICOS, and CD40L on the T cell with
CD80 and CD86, ICOSL, and CD40 on
DCs and B cells, contribute to the upregu-
lation of the transcription factor Bcl-6
(Figure 1), a signature regulator promoting
the development of Tfh cells (Crotty,
2011). The Tfh-helped B cells or centro-
blasts proliferate and express activation-
induced cytidine deaminase to undergo
somatic hypermutation (SHM) in the V
region of their B cell receptor (BCR). This
process produces B cell clones that bind
the immunizing antigen with higher affinity
and are selected to survive by interaction
with the antigen-specific Tfh cells in the
GCs. Thus, GC formation is a highly regu-
lated process involving a large number of
molecular interactions that promote
differentiation of Tfh and B cells neces-
sary for the production of high-affinity iso-
type class switched antibodies as well as
immunological memory (Figure 1).
In the current issue of Immunity, Balles-
teros-Tato et al. (2012) show that the
amounts of interleukin-2 (IL-2) in vivo
also importantly influence whether devel-
oping CD4+ T effector cells choose a Tfh
cell fate. The key point is that an environ-
ment low in IL-2 favors Tfh cells. The main
approach used was to follow the immune702 Immunity 36, May 25, 2012 ª2012 Elseviresponse in mice infected with influenza
virus that were untreated or received
twice daily injections of IL-2 for 3 weeks.
When these IL-2-treated mice were
examined, they showed lower numbers
of influenza-specific IgG secreting B cells.
Their draining lymph nodes exhibited
decreased GC structures that contained
a nearly 80% reduction in B cells that ex-
pressed markers (PNAhi Fas+) character-
istic of GCs and were specific for the
influenza nucleoprotein (NP). To examine
the cellular basis of this response, the
authors generated chimeras by reconsti-
tuting lethally irradiated mice with equal
numbers of congenic-marked bone
marrow from WT or IL-2 receptor-defi-
cient (Cd25/) donors. When these re-
constituted mice were infected with
influenza, treatment with IL-2 had no
effect on the B cell compartment, i.e.,
GC-derived B cells that produced NP-
specific IgG antibodies were readily de-
tected and these were equally distributed
between WT and Cd25/ B cells. How-
ever, when the T cell compartment was
examined, a 3- to 4-fold increase was
noted in the numbers of PD-1+ CXCR5+
NP-specific Tfh cells of Cd25/ origin.
Examination of NP-specific T cells from
normal mice infected with influenza
showed that Tfh cells expressed low
amount of CD25, consistent with cells
that received low IL-2R signaling and
were characterized by high expression
of Bcl-6 and ICOS. These latter two mole-
cules on NP-specific T cells were both
reduced in the presence of IL-2. Thus,
increasing IL-2 did not intrinsically alter
the B cell compartment but rather
affected Tfh cells.
IL-2R signaling activates three main
signaling pathways in T cells: MAPK,
PI3K, and STAT5. Recent work has shown
that IL-2-dependent activation of STAT5er Inc.is largely responsible for negatively regu-
lating Tfh cell development (Johnston
et al., 2012). This finding is highly reminis-
cent of the inhibitory role of IL-2 in the
generation of T helper 17 (Th17) cells
through STAT5 activation (Laurence
et al., 2007).With respect to Tfh cells, acti-
vated lymphocytic choriomeningitis virus
(LCMV)-specific T cell receptor trans-
genic CD4+ T cells were engineered
in vitro to overexpress active STAT5 or
to lack STAT5 expression. When such
cells were transferred to mice and in-
fected with LCMV, increased STAT5
activation was associated with lower Tfh
cells whereas lower STAT5 supported
increased Tfh cell development and GCs
(Johnston et al., 2012). Antigen-activated
T cells expressing low amount of Blimp-1
(encoded by Prdm1), a repressor of
Bcl-6, also supported Tfh cell develop-
ment, further implicating regulation of
Bcl-6 in this process.
The data from these two papers (Balles-
teros-Tato et al., 2012; Johnston et al.,
2012) support a model in which the
amount of IL-2, STAT5, Blimp-1, and
Bcl-6 are linked not only to the decision
to adopt a Tfh cell fate but also to other
T effector subsets and memory cells
(Figure 1). During a specific immune
response in which IL-2 expression is rela-
tively high, IL-2-dependent STAT5 activa-
tion is more prolonged, supporting
STAT5-dependent activation of Blimp-1.
High amounts of Blimp-1 are associated
with terminal differentiation of several
cells types, including plasma cells and T
effector cells. For T cells, high IL-2 and
Blimp-1 are associated with production
of short-lived CTL, Th2 cells, and
a subpopulation of activated Treg cells.
In settings where IL-2 is limited, Blimp-1
is not substantially expressed because
of low activation of STAT5, thus
Figure 1. High IL-2 Expression Opposes Tfh Cell Development
Under low IL-2 conditions (top), antigen-activated CD4+ T cells express high amounts of CXCR5, ICOS,
Bcl-6, and PD-1 and efficiently develop into Tfh cells. CD25 expression in Tfh cells is relatively low, indic-
ative of a cell encountering low IL-2. Tfh cells promote GC formation within the B cell follicles. These tran-
sient structures facilitate B cell differentiation, including production of high-affinity isotype switched IgG
antigen-specific antibodies and memory B cells. In contrast (bottom), high IL-2 expression, via STAT5-
dependent upregulation of Blimp-1 (Prdm1), represses the Tfh cell signature transcription factor Bcl-6
(Bcl6) to block the development of Tfh cells. Lower production of Tfh cells impairs the GC reaction and
maturation of humoral immune responses. Thus, high IL-2 amounts interfere with the GC reaction and
an effective antibody response.
Immunity
Previewspromoting higher Bcl-6 expression that
supports Tfh cell development and CD8+
T cell memory commitment. However,
amounts of Blimp-1 and Bcl-6 probably
only partially explain these basic and crit-
ical cell fate decisions during an immune
response. For example, IL-2-dependent
STAT5 activation also opposes Th17
development. However, the available
evidence suggests that Th17 cell fate is
dictated by the transcription factor RORgt
rather than expression of Bcl-6 and
Blimp-1. In a related manner, although
IL-2 and STAT5 positively support Treg
cells and CTL, comparatively lower
amounts of IL-2 support Treg cell devel-
opment and homeostasis (Yu et al.,
2009). Thus, the availability of IL-2 may
represent a critical rheostat that is linked
to major cell fate choices dictating the
types of effector T cells while also sup-
porting T memory cell development.
Expression of IL-2 is tightly controlled
transcriptionally and posttranscription-
ally. It was generally believed that this
high regulation is required to critically
control the magnitude of an immune
response. However, both these studies(Ballesteros-Tato et al., 2012; Johnston
et al., 2012) add to the growing body of
evidence that substantial expansion of
antigen-activated T cell clones can occur
in the complete absence of IL-2. Further,
these types of responses remained armed
to control an infection because develop-
ment of Tfh and Th17cells do not require
IL-2 and other effector responses still
somewhat develop independently of IL-2
in vivo. The exquisite control of IL-2
may actually represent a fundamental
mechanism to fine-tune the type and
magnitude of T effector and memory cells
and consequently antigen-specific anti-
body responses.
The interworkings of an immune
response are probably much more subtle
than the nonphysiological approaches
used to uncover IL-2-dependent STAT5
repression of Tfh cells in which IL-2 was
systemically applied for a considerable
time after viral challenge or where the
STAT5 pathway was substantially altered
in activated T cells (Ballesteros-Tato et al.,
2012; Johnston et al., 2012). There remain
several key missing links to better under-
standing IL-2 in this role of dictating cellImmunityfate choices. One fundamental issue is
that we still have a very rudimentary
understanding of when and where IL-2 is
produced in vivo during an ongoing
immune response to regulate Tfh and
Th17 cell development versus supporting
Treg cell homeostasis. Thus, it will be crit-
ical to identify the cell type(s) that produce
IL-2 and amount of IL-2 in the natural
microenvironment where T cells border
the GCs and within the GCs where Tfh
and B cells interact. Another key point is
that the role of Treg cells in regulating
the GC reaction is likely to be complex.
Activated Treg cells reside in the GC and
act to limit Tfh cell numbers (Chung
et al., 2011; Linterman et al., 2011).
However, Treg cells may also lower the
available IL-2 by preferential consumption
through their high expression of IL-2R to
provide an environment to favor Tfh cell
development. In this context, although
the repression of Tfh cell development
by IL-2 is T cell intrinsic, depletion of
Treg cells exaggerated the capacity of
exogenous IL-2 to oppose Tfh cell
production probably by providing surplus
IL-2 (Ballesteros-Tato et al., 2012). Future
work must resolve whether the physiolog-
ical role of Treg cells is to inhibit or
promote Tfh cell production. Alternatively,
both mechanisms may operate but in
a contextual and/or a temporal distinct
manner. Lastly, although lowering IL-2-
dependent activation of STAT5 in T
effector cells is critical for their develop-
ment into Tfh cells, IL-2 also readily acti-
vates the MAPK and PI3K pathways in
conventional activated T cells. The extent
that these pathwaysmight influence these
cell fate choices requires further study.
These new findings have important
implications for exquisite control of IL-2
to prevent pathological consequences
during an immune response as well as
for use of IL-2 in therapeutic settings.
The efficacy of T cell-dependent humoral
immunity is facilitated by Tfh cell help by
promoting SHM, a process involving
DNA recombination. Therefore, the matu-
ration of Ab responses predisposes the
host to the risks of autoimmunity by
altering BCR binding that may recognize
self-antigens andmalignancies as a result
of chromosomal translocations associ-
ated with DNA recombination events.
Thus, precise amounts of local IL-2 may
provide a mechanism to prevent these
potential pathological consequences of36, May 25, 2012 ª2012 Elsevier Inc. 703
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ment and expansion of Tfh cells. In the
context of IL-2 therapy, much emphasis
in the past has been placed on boosting
immunity, particularly in individuals with
cancer or HIV-AIDS, but with limited
success. Besides boosting Treg cells
and immunosuppression, other unin-
tended consequences of adjuvant IL-2
therapy that might compromise its effi-
cacy are reduced Th17 cell and antibody
responses, the latter through interfering
with Tfh cell development (Figure 1).
Thus, elevated IL-2 may be dually immu-
nosuppressive by preventing develop-
ment of Tfh and Th17 cells as well as by
expanding Treg cells. Alternatively, low-
dose IL-2 therapy was effective in pre-
venting and reversing autoimmunity in
preclinical mouse models and in amelio-
rating severe symptoms associated with704 Immunity 36, May 25, 2012 ª2012 Elsevigraft versus host disease and hepatitis c
virus-induced vasculitis in limited clinical
testing (Koreth et al., 2011; Saadoun
et al., 2011). Although these studies
have focused on the positive effects of
IL-2 on Treg cells, the benefit of this
therapy may also reflect the blockade of
Th17 and Tfh cells. These effects of IL-2
should now also be considered when
IL-2 is used in the clinic.
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